



## CORPORATE INFORMATION

Autumn 2008

### Company

Lumavita is a newly-formed, privately owned, specialty biopharmaceutical company focused on the global development and commercialisation of novel anti-infectives for women's health. This is a highly attractive market as many current treatments fail to meet the needs of patients, especially women for whom there has been little anti-infective innovation in recent years.

Lumavita is uniquely positioned as the only specialty biopharmaceutical company dedicated to developing and marketing new molecular entities to combat infections for women's health, addressing major therapeutic needs in large global markets. The company is located in Basel, Switzerland.

### Product Pipeline

Lumavita's proprietary product portfolio contains one project in pre-approval, one in clinical development and one in late-stage pre-clinical development.

Project	Compound	Indication	CMC	PC	Ph1	Ph2	Ph3	Submission or Market
FemiFect® 3mg (low dose)	pentamycin (broad-spectrum macrolide)	Vaginitis 5-10 day treatment						Switzerland Latin America, CIS, North Africa and Asia
FemiFect® (dose optimised)	pentamycin (broad-spectrum macrolide)	Vaginitis 3 day treatment						
LMV-601	PC-PLC Inhibitor* New class of anti-virals	Human Papiloma Virus						
LMV-601	PC-PLC Inhibitor* New class of anti-virals	Herpes Simplex Virus						

\* Inhibitor of phosphatidylcholine phospholipase C. Blocks viral DNA replication and gene expression

2008  
2009

- FemiFect®:** Lumavita's first product is low dose FemiFect®, a broad-spectrum macrolide antibiotic (pentamycin) for the treatment of vaginitis. It is awaiting approval in Switzerland and the company anticipates its launch in early 2009. Additional regulatory submissions are pending in Latin America, CIS and Asia. The worldwide market for vaginitis generates 110 million prescriptions each year and is estimated to be worth over \$2.4 billion.

FemiFect® is the first broad-spectrum antibiotic for the treatment of all three most common causes of vaginitis: bacteria, fungi and protozoa. Once established as a first-line treatment, low dose FemiFect® will be followed by a dose optimized version which will reduce the number of treatment days to three. Lumavita is currently undertaking a Phase IIb dose-optimisation programme in this regard.

- LMV-601:** Lumavita is leading the field in the research and development of a new class of anti-viral compounds known as PC-PLC (phosphatidylcholine-specific phospholipase C) inhibitors. PC-PLC inhibitors act on the host cell and not on the virus directly by blocking viral replication within the host cell. Two key benefits of this approach are the broad-spectrum of anti-viral activity of PC-PLC inhibitors, which result in increased efficacy and the potential to treat late-stage lesions, which are key limitations of current treatments.

LMV-601 is the first compound in development in this new class of anti-viral drugs with an entirely novel mechanism of action. It is currently in late-stage pre-clinical development for the treatment of HPV, a major cause of cervical cancer.

"Lumavita is a patient-focused company, committed to developing treatments that will make a real difference to people's lives."

Nicholas Benedict,  
Chief Executive  
Officer



### Opportunity

Vaginitis is a very common disorder affecting up to 10% of women annually and includes conditions such as candidiasis, trichomonas and bacterial vaginosis. However, limitations with existing treatments result in many patients failing to respond adequately and recurrence rates are around 40%.

The World Health Organisation estimates that the world prevalence of HPV infection is between 9% and 13% of the adult population and it is the most commonly diagnosed sexually transmitted infection in the USA. HPV treatments represent a \$1.1 billion market opportunity. LMV-601 may also have the potential for treating other viruses such as HSV, H5N1, SARS and CMV.

By focusing on these well-defined markets in which the key prescribers are gynaecologists, Lumavita has the opportunity to build a unique specialty biopharmaceutical company with a low risk profile.

### Commercialisation

Lumavita has established a network of partnerships with distributors in Switzerland, Latin America, Asia and CIS in preparation for the launch of FemiFect®. Partners are meeting all local regulatory, marketing and distribution costs directly which will maximize Lumavita's return on investment.

Lumavita retains all rights to FemiFect® in the world's key markets. Commercialisation options for high dose FemiFect® remain open including the potential for Lumavita to build its own sales and marketing infrastructure targeted to gynaecologists.

### Management

Lumavita has already established a strong team that combines the anti-infective discovery and development expertise of the founder and Chief Scientific Officer, Dr Cees Winnips, with that of CEO, Nicholas Benedict, who has a significant track record in commercialisation within the pharma and biotech industries.

### Senior Team

Nicholas Benedict, Chief Executive Officer  
Cees Winnips M.D., Chief Scientific Officer  
Markus Brand, Director Finance and Accounting  
Michael Tintiuc, Director Business Development  
Dr. Manfred Schulz, Head of Project Management

### Funding

Lumavita raised CHF 18 million (€11 million) on its inception in September 2008 from top tier institutional life science investors including Atlas Venture, BB Biotech Ventures, BioMedInvest and EndeavourVision.

### Contacts

For further information on Lumavita and its products, please visit

<http://www.lumavita.com>

or contact:

Lumavita AG  
Engelgasse 77  
4052 Basel  
Switzerland

P: +41 61 225 4102  
[info@lumavita.com](mailto:info@lumavita.com)

